![]() |
| Source: New York Stock Exchange |
DentalGoodNews|On November 13, 2026, Swiss dental medical technology company vVARDIS Holding AG (NYSE: VVVV, hereinafter "vVARDIS") listed on the New York Stock Exchange (NYSE). The company's Initial Public Offering (IPO) comprised 9,722,223 Class A ordinary shares at an issue price of US$18 per share, raising approximately US$175 million (before deducting underwriting discounts and offering expenses). The closing price on the first day of trading was US$16.50 per share, implying a market capitalization of approximately US$2.99 billion (approximately RMB 21 billion).
The IPO was jointly led by Goldman Sachs and J.P. Morgan as joint book-running managers, with William Blair, UBS and Deutsche Bank acting as underwriters.
According to the company's announcement on November 13, the IPO issue price was US$18, below the previously disclosed range of US$21–24 in the prospectus. The company also granted the underwriters a 30-day over-allotment option to purchase up to an additional 1,458,333 Class A ordinary shares. The offering is expected to close on or about November 16, subject to the satisfaction of customary closing conditions.
vVARDIS is headquartered in Zug, Switzerland, and its core business is the development of dental medical technology products, primarily offering non-invasive Dental Caries treatment products under the Curodont® brand. The company's core products use a peptide-containing formulation and primarily target early-stage, non-cavitated lesions classified as ICDAS 1 and 2, providing a non-invasive treatment option; clinical procedures require no mechanical drilling, injections or anesthesia, and Chairside procedure time can be kept under 5 minutes. According to company estimates, as of June 30, 2026, its products had treated more than 3.5 million teeth cumulatively, and its flagship product had been sold to more than 20,000 of the approximately 110,000 general dental practices in the United States.
According to the F-1 registration statement vVARDIS filed with the Securities and Exchange Commission (SEC) on October 9, 2026, the company's net revenue was US$30.2 million in 2025; net revenue for the first half of 2026 was US$28.6 million, up 214.2% year over year, with gross profit of US$24.7 million and a Gross Margin of 86.4%. However, the company's net loss for the same period still amounted to US$27.8 million.
![]() |
| Source: F-1 registration statement filed by vVARDIS |
On the financing side, vVARDIS secured US$35 million in initial financing and US$50 million in additional financing from global healthcare investment firm OrbiMed in 2025, bringing cumulative financing to US$85 million. In April 2026, the company also announced a strategic minority equity investment from a fund under Apollo Global Management, without disclosing the specific transaction amount.
| About DGN:DentalGoodNews (DGN) is a trusted professional media platform dedicated to the global dental industry. We deliver in-depth coverage of corporate news, policy & regulation, investment & funding, and clinical frontiers — serving dental institutions, device manufacturers, investors, and industry researchers worldwide. Contact us: haodeya@dongxizixun.com |